Abstract
Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes, and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.
Original language | English (US) |
---|---|
Journal | Current Cardiovascular Risk Reports |
Volume | 9 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2015 |
Keywords
- Antiplatelet
- Antiplatelet resistance
- Aspirin resistance
- Clopidogrel resistance
- Diabetes mellitus
- High on-treatment platelet reactivity
- Platelets
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)